Literature DB >> 10567244

Design of an adenosine phosphorylase by active-site modification of murine purine nucleoside phosphorylase. Enzyme kinetics and molecular dynamics simulation of Asn-243 and Lys-244 substitutions of purine nucleoside phosphorylase.

J T Maynes1, W Yam, J P Jenuth, R Gang Yuan, S A Litster, B M Phipps, F F Snyder.   

Abstract

Our objective was to alter the substrate specificity of purine nucleoside phosphorylase such that it would catalyse the phosphorolysis of 6-aminopurine nucleosides. We modified both Asn-243 and Lys-244 in order to promote the acceptance of the C6-amino group of adenosine. The Asn-243-Asp substitution resulted in an 8-fold increase in K(m) for inosine from 58 to 484 microM and a 1000-fold decrease in k(cat)/K(m). The Asn-243-Asp construct catalysed the phosphorolysis of adenosine with a K(m) of 45 microM and a k(cat)/K(m) 8-fold that with inosine. The Lys-244-Gln construct showed only marginal reduction in k(cat)/K(m), 83% of wild type, but had no activity with adenosine. The Asn-243-Asp;Lys-244-Gln construct had a 14-fold increase in K(m) with inosine and 7-fold decrease in k(cat)/K(m) as compared to wild type. This double substitution catalysed the phosphorolysis of adenosine with a K(m) of 42 microM and a k(cat)/K(m) twice that of the single Asn-243-Asp substitution. Molecular dynamics simulation of the engineered proteins with adenine as substrate revealed favourable hydrogen bond distances between N7 of the purine ring and the Asp-243 carboxylate at 2.93 and 2.88 A, for Asn-243-Asp and the Asn-243-Asp;Lys-244-Gln constructs respectively. Simulation also supported a favourable hydrogen bond distance between the purine C6-amino group and Asp-243 at 2.83 and 2.88 A for each construct respectively. The Asn-243-Thr substitution did not yield activity with adenosine and simulation gave unfavourable hydrogen bond distances between Thr-243 and both the C6-amino group and N7 of the purine ring. The substitutions were not in the region of phosphate binding and the apparent S(0.5) for phosphate with wild type and the Asn-243-Asp enzymes were 1.35+/-0.01 and 1.84+/-0.06 mM, respectively. Both proteins exhibited positive co-operativity with phosphate giving Hill coefficients of 7.9 and 3.8 respectively.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10567244      PMCID: PMC1220679     

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  34 in total

1.  Three-dimensional structure of human erythrocytic purine nucleoside phosphorylase at 3.2 A resolution.

Authors:  S E Ealick; S A Rule; D C Carter; T J Greenhough; Y S Babu; W J Cook; J Habash; J R Helliwell; J D Stoeckler; R E Parks
Journal:  J Biol Chem       Date:  1990-01-25       Impact factor: 5.157

2.  Purine nucleoside phosphorylase. Allosteric regulation of a dissociating enzyme.

Authors:  P A Ropp; T W Traut
Journal:  J Biol Chem       Date:  1991-04-25       Impact factor: 5.157

3.  Nucleotide sequence of murine purine nucleoside phosphorylase cDNA.

Authors:  J P Jenuth; F F Snyder
Journal:  Nucleic Acids Res       Date:  1991-04-11       Impact factor: 16.971

4.  Computer analysis of enzyme-substrate-inhibitor kinetic data with automatic model selection using IBM-PC compatible microcomputers.

Authors:  R A Lutz; C Bull; D Rodbard
Journal:  Enzyme       Date:  1986

5.  Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity.

Authors:  E R Giblett; J E Anderson; F Cohen; B Pollara; H J Meuwissen
Journal:  Lancet       Date:  1972-11-18       Impact factor: 79.321

6.  Inhibition of human purine nucleoside phosphorylase. Studies with intact erythrocytes and the purified enzyme.

Authors:  T A Krenitsky; G B Elion; A M Henderson; G H Hitchings
Journal:  J Biol Chem       Date:  1968-06-10       Impact factor: 5.157

Review 7.  Trends in the biochemical pharmacology of 5'-deoxy-5'-methylthioadenosine.

Authors:  H G Williams-Ashman; J Seidenfeld; P Galletti
Journal:  Biochem Pharmacol       Date:  1982-02-01       Impact factor: 5.858

8.  Nucleoside-phosphorylase deficiency in a child with severely defective T-cell immunity and normal B-cell immunity.

Authors:  E R Giblett; A J Ammann; D W Wara; R Sandman; L K Diamond
Journal:  Lancet       Date:  1975-05-03       Impact factor: 79.321

9.  Purine nucleoside phosphorylase from human erythrocytes: physiocochemical properties of the crystalline enzyme.

Authors:  J D Stoeckler; R P Agarwal; K C Agarwal; K Schmid; R E Parks
Journal:  Biochemistry       Date:  1978-01-24       Impact factor: 3.162

10.  Characterization of purine nucleoside phosphorylase from human granulocytes and its metabolism of deoxyribonucleosides.

Authors:  D A Wiginton; M S Coleman; J J Hutton
Journal:  J Biol Chem       Date:  1980-07-25       Impact factor: 5.157

View more
  2 in total

1.  Humanized ADEPT comprised of an engineered human purine nucleoside phosphorylase and a tumor targeting peptide for treatment of cancer.

Authors:  Sepideh Afshar; Tsuneaki Asai; Sherie L Morrison
Journal:  Mol Cancer Ther       Date:  2009-01       Impact factor: 6.261

2.  FAMIN Is a Multifunctional Purine Enzyme Enabling the Purine Nucleotide Cycle.

Authors:  M Zaeem Cader; Rodrigo Pereira de Almeida Rodrigues; James A West; Gavin W Sewell; Muhammad N Md-Ibrahim; Stephanie Reikine; Giuseppe Sirago; Lukas W Unger; Ana Belén Iglesias-Romero; Katharina Ramshorn; Lea-Maxie Haag; Svetlana Saveljeva; Jana-Fabienne Ebel; Philip Rosenstiel; Nicole C Kaneider; James C Lee; Trevor D Lawley; Allan Bradley; Gordon Dougan; Yorgo Modis; Julian L Griffin; Arthur Kaser
Journal:  Cell       Date:  2020-01-23       Impact factor: 41.582

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.